Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.
drug-resistant epilepsy
epilepsy with eyelid myoclonia
eyelid myoclonia
genetic generalized epilepsy
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
24
05
2023
received:
28
04
2023
accepted:
13
06
2023
medline:
20
9
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
There are limited data about the treatment and management of epilepsy with eyelid myoclonia (EEM). The objective of this study was to determine areas of consensus among an international panel of experts for the management of EEM (formerly known as Jeavons syndrome). An international steering committee was convened of physicians and patients/caregivers with expertise in EEM. This committee summarized the current literature and identified an international panel of experts (comprising 25 physicians and five patients/caregivers). This panel participated in a modified Delphi process, including three rounds of surveys to determine areas of consensus for the treatment, other areas of management, and prognosis for EEM. There was a strong consensus for valproic acid as the first-line treatment, with levetiracetam or lamotrigine as preferable alternatives for women of childbearing age. There was a moderate consensus that ethosuximide and clobazam are also efficacious. There was a strong consensus to avoid sodium channel-blocking medications, except for lamotrigine, as they may worsen seizure control. There was consensus that seizures typically persist into adulthood, with remission occurring in <50% of patients. There was less agreement about other areas of management, including dietary therapy, lens therapy, candidacy for driving, and outcome. This international expert panel identified multiple areas of consensus regarding the optimal management of EEM. These areas of consensus may inform clinical practice to improve the management of EEM. In addition, multiple areas with less agreement were identified, which highlight topics for further research.
Substances chimiques
Lamotrigine
U3H27498KS
Anticonvulsants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2342-2350Informations de copyright
© 2023 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Smith KM, Wirrell EC, Andrade DM, Choi H, Trenite DK, Knupp KG, et al. A comprehensive narrative review of epilepsy with eyelid myoclonia. Epilepsy Res. 2023;26(193):107147.
Covanis A. Jeavons syndrome - updated review. J Epileptol. 2015;23:113-23.
Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63:1398.
Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63:1475.
Smith KM, Youssef PE, Wirrell EC, Nickels KC, Payne ET, Britton JW, et al. Jeavons syndrome: clinical features and response to treatment. Pediatr Neurol. 2018;86:46-51.
Zawar I, Toribio MGG, Xu X, Alnakhli RS, Benech D, Valappil AMN, et al. Epilepsy with eyelid myoclonias - a diagnosis concealed in other genetic generalized epilepsies with photoparoxysmal response. Epilepsy Res. 2022;181:106886.
Irelli EC, Cocchi E, Ramantani G, Caraballo RH, Giuliano L, Yilmaz T, et al. Electroclinical features and long-term seizure outcome in patients with eyelid Myoclonia with absences. Neurology. 2022;98:e1865.
Giuliano L, Fatuzzo D, Mainieri G, Maira G, Elia M, Ferlazzo E, et al. Eyelid myoclonia with absences: electroclinical features and prognostic factors. Epilepsia. 2019;60:1104-13.
Smith KM, Wirrell EC, Andrade DM, Choi H, Trenite DK, Jones H, et al. Clinical presentation and evaluation of epilepsy with eyelid myoclonia: results of an international expert consensus panel. Epilepsia. 2023; https://doi.org/10.1111/epi.17683
Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health. 2020;8:457.
Parissis D, Ioannidis P, Karacostas D. Levetiracetam as alternative treatment in Jeavons syndrome. J Neurol Sci. 2014;15(341):147-9.
Abdulla H, Mirza M, Osman S, Dunne K. Jeavons syndrome. Bahrain Med Bull. 2016;38:105-7.
Singla S, Sureshbabu S, Razora D, Mittal GK, Peter S, Chindripu S, et al. Electro-clinical expression and pharmaco-therapeutic options in Jeavons syndrome-case report and review of literature. India J Medical Spec. 2017;8:217-20.
Striano P, Sofia V, Capovilla G, Rubboli G, Di Bonaventura C, Coppola A, et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia. 2008;49:425-30.
Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome. A Randomized Clinical Trial. JAMA Neurol. 2022;1(79):554-64.
Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;21(394):2243-54.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018 May;17(378):1888-97.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;25(376):2011-20.
Geenen KR, Doshi SP, Patel S, Sourbron J, Falk A, Morgan A, et al. Fenfluramine for seizures associated with sunflower syndrome. Dev Med Child Neurol. 2021;63:1427-32.
Zillgitt AJ, Haykal MA, Chehab A, Staudt MD. Centromedian thalamic neuromodulation for the treatment of idiopathic generalized epilepsy. Front Hum Neurosci. 2022;16:907716.
Kokkinos V, Urban A, Sisterson ND, Li N, Corson D, Richardson RM. Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalized epilepsy: a case report. Neurosurgery. 2020;15(87):E578-83.
Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia. 1997;38:233-6.
Krumholz A. Driving issues in epilepsy: past, present, and future. Epilepsy Curr. 2009;9:31-5.
Kasteleijn-Nolst Trenite DG, Riemersma JB, Binnie CD, Smit AM, Meinardi H. The influence of subclinical epileptiform EEG discharges on driving behaviour. Electroencephalogr Clin Neurophysiol. 1987;67:167-70.
Antwi P, Atac E, Ryu JH, Arencibia CA, Tomatsu S, Saleem N, et al. Driving status of patients with generalized spike-wave on EEG but no clinical seizures. Epilepsy Behav. 2019;92:5-13.
Striano S, Striano P, Nocerino C, Boccella P, Bilo L, Meo R, et al. Eyelid myoclonia with absences: an overlooked epileptic syndrome? Neurophysiol Clin. 2002;32:287-96.
Cerulli Irelli E, Cocchi E, Ramantani G, Riva A, Caraballo RH, Morano A, et al. The spectrum of epilepsy with eyelid myoclonia: delineation of disease subtypes from a large multicenter study. Epilepsia.2023;64:196-207.
Destina YalcinA, FortaH, KilicE. Overlap cases of eyelid myoclonia with absences and juvenile myoclonic epilepsy. Seizure. 2006;15:359-65.
StrianoS, CapovillaG, SofiaV, RomeoA, RubboliG, StrianoP, et al. Eyelid myoclonia with absences (Jeavons syndrome): a well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions? Epilepsia. 2009;50(Suppl 5):15-9.